Clinical and Laboratory Evaluations of Patients Diagnosed as Having Multisystem Inflammatory Syndrome Associated with Coronavirus Disease 2019 in Children: A Single Center Experience from Konya
Journal of Pediatric Infectious Diseases
; 18(1):17-24, 2023.
Article
in English
| Scopus | ID: covidwho-2240923
ABSTRACT
Objective Multisystem inflammatory syndrome in children (MIS-C), characterized by fever, inflammation, and multiorgan dysfunction, was newly defined after severe acute respiratory syndrome coronavirus 2 infection. The clinical spectrum of MIS-C can be classified as mild, moderate, and severe. We aimed to evaluate demographics, clinical presentations, laboratory findings, and treatment modalities of patients with MIS-C according to clinical severity. Methods We performed a retrospective study of patients who were diagnosed as having MIS-C between September 2020 and October 2021 in the Necmettin Erbakan University Meram Faculty of Medicine, Türkiye. Results A total of 48 patients (24 females and 24 males) with a median age at diagnosis of 10.3 years (range 42 months-17 years) were enrolled, the most common clinical severity of MIS-C was moderate. The common presentations of patients were fever (97%), nonpurulent conjunctivitis (89.6%), rashes (81.3%), fatigue (81.3%), strawberry tongue (79.2%), and myalgia (68.8%). The most common laboratory findings were lymphopenia (81.2%), thrombocytopenia (54.1%), elevated D-dimer levels (89.5%), C-reactive protein (CRP;100%), procalcitonin (97%), erythrocyte sedimentation rate (87.5%), ferritin (95.8%), interleukin 6 (IL-6) (86.1%), and probrain natriuretic peptide (pro-BNP) (97%). High levels of CRP, procalcitonin, pro-BNP, and urea were associated with the severity of MIS-C (p < 0.05). Fifteen of the patients were found to have pulmonary involvement. Ascites were the most common finding on abdominal ultrasonography (11 patients) and were not seen in a mild form of the disease. During the study period, two patients died. Conclusion It is important to make patient-based decisions and apply a stepwise approach in treating patients with MIS-C due to the increased risk of complications and mortality. © 2022. Thieme. All rights reserved.
acetylsalicylic acid; amino terminal pro brain natriuretic peptide; anakinra; antibiotic agent; C reactive protein; cyclosporine; D dimer; enoxaparin; ferritin; immunoglobulin; inotropic agent; interleukin 6; low molecular weight heparin; methylprednisolone; procalcitonin; tocilizumab; urea; abdominal radiography; abnormal value; adolescent; antibiotic therapy; Article; cardiogenic shock; child; clinical article; clinical evaluation; clinical feature; conjunctivitis; coronavirus disease 2019; corticosteroid therapy; death; demographics; disease association; disease severity; drug dose reduction; echography; erythrocyte sedimentation rate; experience; fatigue; female; fever; human; immunosuppressive treatment; immunotherapy; laboratory test; lung disease; lymphocytopenia; macrophage activation syndrome; male; myalgia; pediatric multisystem inflammatory syndrome; pediatric patient; plasmapheresis; rash; retrospective study; single drug dose; strawberry tongue; thrombocytopenia; tongue disease; Turkey (republic); university hospital; clinical and laboratory findings; COVID-19; Multisystem inflammatory syndrome in children
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Journal of Pediatric Infectious Diseases
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS